INTRODUCTION AND OBJECTIVES:
A statistical model based on a panel of four kallikrein (4K) markers in blood-commercially available as 4Kscore-can accurately predict high-grade (!Grade Group [GrdGrp] 2) prostate cancer (PC) on biopsy. However, sampling error and variation in pathology reporting may miss aggressive disease. We evaluated the ability of the 4K panel to predict adverse pathology at radical prostatectomy (RP)-the gold standard for accurate histological diagnosis, and biochemical recurrence (BCR) after RP.
METHODS: The 4K panel was measured in cryopreserved blood from 2,330 patients obtained before RP at a tertiary referral center between [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] . Adverse pathology at RP was defined as: primary Gleason grade 4, any grade 5, seminal vesicle invasion, extracapsular extension or lymph node invasion. BCR was defined as prostate specific antigen (PSA) ! 0.20 µg/L. Multivariable (logistic and Cox) regression was used to study the association between the 4K panel, adverse pathology, and BCR, respectively. Discrimination was assessed by the area under the curve (AUC) and Harrel's concordance (C) index, comparing the improvement in discrimination by adding the pre-specified 4K panel-based model to a preoperative clinical base model (age, PSA, clinical stage and grade). Clinical utility was assessed using decision curve analysis. We prespecified that we would separately assess men with GrdGrp1-where the clinical decision concerns obtaining a confirmatory biopsy-and GrdGrp2-where the decision concerns active surveillance vs. treatment.
RESULTS: The median age was 64 years and the median followup was 7.8 years. On multivariable logistic regression, the 4K panel was significantly associated with adverse pathology ( 
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INTRODUCTION AND OBJECTIVES: Prostate volume is a strong predictor of prostate biopsy outcome, but requires an additional procedure (transrectal ultrasound [TRUS] or MRI) and is thus generally not included in biopsy prediction models. The four kallikrein panelcommercially available as the 4Kscore -is widely used to predict the risk of high grade (Gleason grade group [GGG] 2þ) disease and requires only a blood draw. As volume measurements may be available for some men -such as those with prior negative biopsies or on active surveillance -we aimed to assess whether adding prostate volume to the 4kscore would improve discrimination for GGG2þ disease. METHODS: 9,131 patients with available prostate volume from TRUS and total PSA 25 ng/ml from 9 research cohorts were included in this analysis, including 5 historical cohorts (sextant biopsy, pre-ISUP 2005 grading) and 4 contemporary cohorts (10þ cores, ISUP 2005 grading). Previously published models were used to predict risk of GGG2þ based on the kallikrein panel. The difference in discrimination between the kallikrein panel and kallikrein panel þ volume models was calculated for each cohort and entered into a meta-analysis.
RESULTS: Increased prostate volume was found to be associated with a significantly lower risk of GGG2þ disease after controlling for kallikrein panel score in 6 out of 9 cohorts, but volume did not add discrimination. The meta-analytic estimate of discrimination of 0.817 (95% CI 0.802, 0.831) for the kallikrein panel was not improved after including prostate volume (difference in AUC -0.003, 95% CI -0.015, 0.009). There was significant heterogeneity (p[0.002) driven by an increase in AUC in a cohort of academic centers (0.044, 95% CI 0.022, 0.066). No increase in AUC was seen in any other cohort and there was no evidence of heterogeneity after exclusion of academic centers(p[0.7). In a sensitivity analysis, addition of prostate volume Vol. 201, No. 4S, Supplement, Friday, May 3, 2019 THE JOURNAL OF UROLOGY Ò e269
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